T3D Therapeutics, Inc., a clinical-stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Robert Alexander has joined the Company’s Scientific Advisory Board.
CEO John Didsbury states,
“As we advance the clinical development of our drug candidate, T3D-959, beyond our completed Phase 2 PIONEER trial, Dr. Alexander’s expertise in Alzheimer’s drug development and regulatory affairs will be invaluable.”
Dr Robert Alexander is currently the Chief Scientific Officer of the Alzheimer’s Prevention Initiative at the Banner Alzheimer’s Institute and a Research Professor in the Department of Psychiatry at the University of Arizona School of Medicine-Phoenix. Previously, he held positions as VP in the neuroscience therapeutic area unit at Takeda, VP and head of clinical for the neuroscience and pain at Pfizer, VP of clinical for CNS and the pain innovative medicines unit (iMed) at AstraZeneca, as well as other positions in discovery medicine and neuroscience at GSK and Merck. Dr. Alexander received his M.D. degree from The University of Chicago Pritzker School of Medicine. He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology, having conducted or supervised clinical studies in a broad range of neurologic and psychiatric indications.
“The Phase 2 results of T3D-959 in mild-to-moderate AD patients are compelling and offer the strong potential to have a positive impact on this catastrophic disease. I am looking forward to assisting the Company to help advance this drug to market as expeditiously as possible,” said Dr. Alexander.
About T3D-959: T3D-959, a small molecule, delivered orally once daily, is a brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve both glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders.